ReviewInternational journal of molecular sciences2024
Profound Properties of Protein-Rich, Platelet-Rich Plasma Matrices as Novel, Multi-Purpose Biological Platforms in Tissue Repair, Regeneration, and Wound Healing.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Efficacy of intraovarian autologous platelet-rich plasma in women with poor ovarian reserve or ovarian insufficiency: a meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2026Pooled it
- The effect of platelet-rich plasma on clinical outcomes within two years after anterior cruciate ligament reconstruction: a systematic review and meta-analysis of randomized controlled trials.Journal of orthopaedic surgery and research · 2025Pooled it
- Efficacy and safety of platelet-rich plasma versus conventional care in diabetic foot ulcers: a meta-analysis of randomized controlled trials.Acta diabetologica · 2025Pooled it
- The efficacy of platelet-rich plasma preparation protocols in the treatment of osteoarthritis: a network meta-analysis of randomized controlled trials.Journal of orthopaedic surgery and research · 2025Pooled it
- Efficacy and safety of allogeneic platelet-rich plasma in chronic wound treatment: a meta-analysis of randomized controlled trials.Scientific reports · 2024Pooled it
- A Randomized Controlled Trial of Platelet-Rich Plasma Combined with Fractional COInternational urogynecology journal · 2026Trial
- Management of Musculoskeletal Injuries with an Inflammatory Damage-Associated Molecular Pattern (DAMP) Etiology.Pain and therapy · 2026Review
- Comment on: From fibrosis to restoration: the multimodal 3 Ts protocol for Peyronie's disease.International journal of impotence research · 2026Article
- Platelet-Rich Plasma Modulates Neuroinflammation in an iPSC Model of Sensory Neurons and Microglia.International journal of molecular sciences · 2026Article
- Intervention With Autologous Platelet-Containing Plasma for Immature Atrophic Facial Scars: A Quantitative Case Study.Clinical case reports · 2026Article
- Fibrin-Based Biomaterials in Wound Healing and Soft Tissue Regeneration: Biological Mechanisms and Clinical Applications.Gels (Basel, Switzerland) · 2026Review
- A scoping review on platelet-rich fibrin-driven bone regeneration: biological mechanisms and clinical applications in oral and maxillofacial surgery.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2026Article
- From fibrosis to restoration: the multimodal 3 Ts protocol for Peyronie's disease.International journal of impotence research · 2026Review
- A sequential defense-nourishment strategy enabled by thermosensitive core-shell microneedles for synergistic tendon repair.Materials today. Bio · 2026Article
- Effectiveness of platelet-rich plasma therapy in promoting wound healing and shoulder function recovery after shoulder surgery.Scientific reports · 2026Article
- Platelet-Derived Components for Skin and Bone Aging and Age-Associated Pathologies: Mechanisms, Bioengineering Strategies, and Clinical Translation.Molecules (Basel, Switzerland) · 2026Review
- Empagliflozin and platelet-rich plasma improve stanozolol induced cardiotoxicity by reducing NF-κB/P65, IL-1B and apoptosis.BMC pharmacology & toxicology · 2026Article
- Photothermal conditioning of platelet-rich plasma: mechanisms and emerging applications in hair regeneration.Skin health and disease · 2026Review
- Adjunctive Use of Platelet-Derived Concentrates (Platelet-Rich Plasma, Platelet-Rich Fibrin, Concentrated Growth Factor, Platelet-Poor Plasma) in Non-Surgical Periodontal Therapy: Current Evidence and Comparative Analysis.Journal of clinical medicine · 2026Review
- Platelet Lysate-Based Biomaterials for Regenerative Tissue Engineering: A Comprehensive Review.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autologous platelet-rich plasma (PRP) preparations are prepared at the point of care. Centrifugation cellular density separation sequesters a fresh unit of blood into three main fractions: a platelet-poor plasma (PPP) fraction, a stratum rich in platelets (platelet concentrate), and variable leukocyte bioformulation and erythrocyte fractions. The employment of autologous platelet concentrates facilitates the biological potential to accelerate and support numerous cellular activities that can lead to tissue repair, tissue regeneration, wound healing, and, ultimately, functional and structural repair. Normally, after PRP preparation, the PPP fraction is discarded. One of the less well-known but equally important features of PPP is that particular growth factors (GFs) are not abundantly present in PRP, as they reside outside of the platelet alpha granules. Precisely, insulin-like growth factor-1 (IGF-1) and hepatocyte growth factor (HGF) are mainly present in the PPP fraction. In addition to their roles as angiogenesis activators, these plasma-based GFs are also known to inhibit inflammation and fibrosis, and they promote keratinocyte migration and support tissue repair and wound healing. Additionally, PPP is known for the presence of exosomes and other macrovesicles, exerting cell-cell communication and cell signaling. Newly developed ultrafiltration technologies incorporate PPP processing methods by eliminating, in a fast and efficient manner, plasma water, cytokines, molecules, and plasma proteins with a molecular mass (weight) less than the pore size of the fibers. Consequently, a viable and viscous protein concentrate of functional total proteins, like fibrinogen, albumin, and alpha-2-macroglobulin is created. Consolidating a small volume of high platelet concentrate with a small volume of highly concentrated protein-rich PPP creates a protein-rich, platelet-rich plasma (PR-PRP) biological preparation. After the activation of proteins, mainly fibrinogen, the PR-PRP matrix retains and facilitates interactions between invading resident cells, like macrophages, fibroblast, and mesenchymal stem cells (MSCs), as well as the embedded concentrated PRP cells and molecules. The administered PR-PRP biologic will ultimately undergo fibrinolysis, leading to a sustained release of concentrated cells and molecules that have been retained in the PR-PRP matrix until the matrix is dissolved. We will discuss the unique biological and tissue reparative and regenerative properties of the PR-PRP matrix.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.